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4 Based on the location of the blood vessels, the terminal branches of the portal and the hepatic (central) veins, and the direction of the blood flow, the individual liver lobule can be subdivided into an upstream "periportal" and a downstream "perivenous" (pericentral) region. Hepatocytes located in either of the two regions have different, often complementary functions, as indicated by differences in the content and activity of several metabolic key enzymes (for review see ((Jungermann and Katz, 1989; Gebhardt, 1992) ). This so-called 'zonation' of metabolism in the liver is also of particular impact on the metabolism of pharmaceuticals and xenobiotics, since most of the enzymes involved in the metabolism of such compounds show distinct differences in basal as well as inducible expression between perivenous and periportal hepatocytes, with the main detoxification enzymes of both phase I and phase II of xenobiotic metabolism being located preferentially in perivenous hepatocytes (for reviews on zonation of xenobiotic metabolism see (Jungermann and Katz, 1989; Oinonen and Lindros, 1998) ). As a consequence, various exogenous compounds lead to a preferential damage of hepatocytes located in either the perivenous or periportal area of the liver lobule (for review see (Lindros, 1997) ).
We have recently developed a hypothesis to explain the mechanisms that govern zonal differences in gene expression in liver . According to our hypothesis, two opposing signals, each gradual in nature, dictate the gene expression patterns of hepatocytes within the different areas of the liver lobule. We postulated that a β -Catenin-activating signal which is probably delivered by endothelial cells of the central veins, and a second opposing signal, presumably generated by blood-borne molecules activating a Ras-dependent signaling pathway, trigger perivenous-and periportal-specific mRNA expression profiles. This concept was deduced from the observation of striking similarities in the expression of selected "marker" genes in Ctnnb1 (encoding β -Catenin) and Ha-ras mutated hepatoma cells with their corresponding expression patterns in perivenous and periportal hepatocytes, respectively. We have now extended our previous study and compared the transcriptome of periportal and perivenous hepatocyte subpopulations with that of Ha-ras and Ctnnb1 mutated mouse liver tumors. Datasets on global mRNA expression patterns in mouse liver tumors mutated in either Ha-ras or Ctnnb1 and datasets on global mRNA expression patterns in perivenous and periportal mouse hepatocytes were available to us from previous experiments conducted in our laboratory (Stahl et al., 2005a; Braeuning et al., 2006) . In these studies, gene expression profiles had been analyzed by use of the Affymetrix GeneChip MOE-430A (Affymetrix, Santa Clara, CA, USA) containing approximately 22,600 probe sets including more than 14,000 well-characterized mouse genes. Since the criteria for statistical analysis of expression data varied in the two studies, we re-evaluated the tumor datasets using as discriminators a |log 2 expression ratio| ≥ 1 (equivalent to ≥ 2-fold change) and a threshold of 0.1 for the false discovery rate adjusted p-values to allow a direct comparison with our data on zonal differences in gene expression in normal liver (for further details see (Stahl et al., 2005a; Stahl et al., 2005b; Braeuning et al., 2006) ). The former cutoff was chosen because expression differences smaller than 2-fold are very difficult to detect by quantitative RT-PCR, which was used in the previous studies for verification of the microarray results. The latter was chosen to keep the expected proportion of false-positives below 10%. We have recently determined by microarray analysis the RNA expression profiles of mouse liver tumors harboring activating mutations in either Ha-ras or Ctnnb1 (Stahl et al., 2005a) . In that study, liver tumors of the 2 genotypes were found to differ strikingly with respect to their gene expression patterns. More recently, we performed a microarray analysis of periportal and perivenous subpopulations of mouse hepatocytes enriched by combined digitonin/collagenase perfusion . In this latter study, 198 genes or expressed sequences (corresponding to 243 probe sets) were identified that demonstrated a ≥ 2-fold difference in expression between hepatocytes from the 2 different zones of the liver at a threshold of 0.1 for the false discovery rate adjusted p-values. Since more stringent criteria for statistical significance had been applied in our tumor microarray study, we now reanalyzed the tumor datasets using the same cutoffs as in our study on gene expression in perivenous and periportal hepatocyte subpopulations. Under these conditions, 777 (Ctnnb1) and 1063 (Ha-ras) probe sets were identified representing transcripts that differed in expression from normal liver (for illustration see Figure 1 ). We then used the tumor datasets for a comparison with the gene expression profiles in perivenous and periportal hepatocytes.
Upon overlay of the datasets, we found that 158 of the 243 probe sets (corresponding to 134 of 198 genes or expressed sequences) identified as differentially regulated in the zonation experiment were also present in either one of the two tumor datasets (see With 24 members (22 metabolic enzymes plus two nuclear receptors mediating the induction of xenobiotic metabolizing enzymes, i.e. AhR and CAR), the genes associated to xenobiotic metabolism constitute the largest group of functionally related genes that exhibit significant expression differences between hepatocytes from the two zones of the liver with 19 of them showing a preferentially perivenous zonation and 5 being mainly expressed in periportal hepatocytes . As shown in Table 1 , 9 of these 24 genes were deregulated in both Ctnnb1 and Ha-ras mutated tumors, 13 genes were present in one of the tumor datasets, whereas only 2 genes were not aberrantly expressed in either of the two tumor genotypes. Upon comparison of expression profiles it becomes apparent that most (Matsumoto et al., 2001) . Hepatocytes co-cultured with cells of the endothelial-like line RL-ET-14 express GS when neighboring the endothelial cells (Gebhardt et al., 1998) and GS expression could be inhibited in this system by silencing of isoforms in cultured primary mouse hepatocytes , and thirdly, since mutational activation of Ctnnb1 in liver tumors is able to induce an expression profile of xenobiotic metabolizing enzymes which is highly correlated to that of perivenous hepatocytes (Table 1 ; see also (Loeppen et al., 2005) ). On the other hand, in Ha-ras mutated tumor cells we observed a general downregulation of "perivenous" mRNAs encoding xenobiotic metabolism-related enzymes. This is in line with the observation that an activated version of Ha-ras downregulates AhR function and Cyp1a expression in mammary carcinoma cells and keratinocytes (Reiners et al., 1997) . Often, enzymes which were upregulated in Ctnnb1 mutated tumors were downregulated in Ha-ras mutated hepatomas, suggesting an antagonism of both pathways in the regulation of gene expression. However, since some "periportal" mRNAs were also downregulated in Ha-ras mutated liver tumors, additional signaling cascades different from the β -Catenin or Ha-ras pathway seem to be involved in the regulation of these genes. A candidate signal transducer mediating the "periportal"
11 phenotype of xenobiotic metabolizing enzymes may be growth hormone, since it has been demonstrated to determine the preferential periportal localization of Cyp2c7 in rat liver (Oinonen et al., 2000) .
In summary, our present data clearly demonstrate that the patterns of gene expression in perivenous hepatocytes strongly resemble those of Ctnnb1-mutated hepatoma cells with activated β -Catenin, while the gene expression patterns of periportal hepatocytes resemble those of Ha-ras mutated hepatoma cells. There is convincing evidence from this and previous studies by our and other groups (Cadoret et al., 2002; Loeppen et al., 2002; Benhamouche et al., 2006; Sekine et al., 2006) 
